Literature DB >> 32825964

Thyroid cancer and thyroid autoimmune disease: A review of molecular aspects and clinical outcomes.

Natália Medeiros Dias Lopes1, Hannah Hamada Mendonça Lens1, André Armani2, Poliana Camila Marinello1, Alessandra Lourenço Cecchini3.   

Abstract

Thyroid cancer (TC) is the most prevalent malignant neoplasm that affects the endocrine system. Hashimoto's thyroiditis (HT), also known as chronic lymphocytic thyroiditis, is the most common autoimmune thyroid disease (AITD) that, together with Graves' disease (GD), represent the main autoimmune diseases that affect the thyroid gland. Some studies suggest a greater risk of AITD and the development of TC, while others, investigate its relationship with TC progression and patient prognosis. In this review, we have analyzed published data on the molecular aspects related to the association between AITD and TC, addressing their influence on TC progression, diagnosis, and prognosis of the patients. MEDLINE database (PubMed) platform was used as a search engine and the original articles related to the topic were selected using the keywords combination "thyroid cancer and Hashimoto thyroiditis" or "thyroid carcinoma and thyroid autoimmune disease". After the selection, we categorized the main findings of the papers into four topics: antitumor immunity, tumor progression, diagnosis, and prognosis. Although most of the studies have pointed out the presence of AITD as a factor that increases the risk of TC, few molecular mechanisms to support this conclusion have been described. Additionally, little information is available to explain, pathophysiologically, the effects of autoimmunity in TC diagnosis, progression, and prognosis.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Graves' disease; Hashimoto's thyroiditis; Prognosis; Thyroid cancer

Mesh:

Year:  2020        PMID: 32825964     DOI: 10.1016/j.prp.2020.153098

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  6 in total

1.  Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers.

Authors:  Guoqiao Zheng; Kristina Sundquist; Jan Sundquist; Tianhui Chen; Asta Försti; Akseli Hemminki; Vaclav Liska; Kari Hemminki
Journal:  Clin Epidemiol       Date:  2021-08-04       Impact factor: 5.814

2.  Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study.

Authors:  Tereza Grimmichova; Petra Pacesova; Martin Hill; Barbora Pekova; Marketa Vankova; Jitka Moravcova; Jana Vrbikova; Zdenek Novak; Karolina Mastnikova; Eliska Vaclavikova; Josef Vcelak; Bela Bendlova; Jana Drozenova; Vlasta Sykorova
Journal:  Biomedicines       Date:  2022-04-20

Review 3.  Graves' disease and papillary thyroid carcinoma: case report and literature review of a single academic center.

Authors:  Marilyn A Arosemena; Nicole A Cipriani; Alexandra M Dumitrescu
Journal:  BMC Endocr Disord       Date:  2022-08-09       Impact factor: 3.263

Review 4.  Inflammasome activation as a link between obesity and thyroid disorders: Implications for an integrated clinical management.

Authors:  Rosario Le Moli; Veronica Vella; Dario Tumino; Tommaso Piticchio; Adriano Naselli; Antonino Belfiore; Francesco Frasca
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

5.  Prognosis of papillary thyroid cancer in patients with Graves' disease: a propensity score-matched analysis.

Authors:  Hyungju Kwon; Byung-In Moon
Journal:  World J Surg Oncol       Date:  2020-10-13       Impact factor: 2.754

6.  Long non‑coding RNA expression profiles identify lncRNA‑XLOC_I2_006631 as a potential novel blood biomarker for Hashimoto's thyroiditis.

Authors:  Huiyong Peng; Si Xiong; Xiangmei Ding; Xinyi Tang; Xuehua Wang; Li Wang; Yingzhao Liu
Journal:  Int J Mol Med       Date:  2020-10-13       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.